Metabolism and transporter-mediated drug–drug interactions of the endothelin-A receptor antagonist CI-1034
Jasminder Sahi(Durham University), L Keller(Pfizer (United States)), Yuyang Ye(Pfizer (United States)), Scott Campbell(Pfizer (United States)), Meera Tugnait(Pfizer (United States)), Kelly Rose, Shamsi Raeissi(Pfizer (United States)), Christopher B. Black, Michael Sinz(Rutgers, The State University of New Jersey), Rouchelle Mireles(Pfizer (United States)), Xianxian Zheng, Sonia M. de Morais(Pfizer (United States)), Muhammed F. Hashim(Pfizer (United States))
Cited by 31
Related Papers
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
|Chemical Research in Toxicology|1998|312
Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole
|Oncogene|2006|211
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
|Antimicrobial Agents and Chemotherapy|2012|186
Pharmacokinetic Drug Interactions Involving 17??-Ethinylestradiol
|Clinical Pharmacokinetics|2007|174